Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Technical analysis for shorts & longs -- Ignore unavailable to you. Want to Upgrade?

To: Suresh who wrote (23592)	9/9/1999 1:51:00 PM
From: Clint E.	Read Replies (1) \| Respond to of 68330

Thanks Suresh. Some large blocks in QQQ.

To: Suresh who wrote (23592)	9/9/1999 1:59:00 PM
From: drsvelte	Respond to of 68330

More from theStreet.com.... Shares of biotech companies Idec Pharmaceuticals (IDPH:Nasdaq) and Genentech (DNA:NYSE) were getting killed today, apparently due to rumors circulating at the Carson Group and BioCentury Conference in New York. The rumor was that Idec CEO William Rastetter talked down numbers for third-quarter U.S. sales of its cancer drug Rituxan. The drug is jointly sold by Idec and Genentech, and the rumor is they would miss the high end of the range and the whisper number. But the company said in fact, the high-end estimate of $80 million in U.S. sales is "achievable," according to a hedge fund analyst who attended the breakout session. Wall Street's consensus for Rituxan's third-quarter sales rests in the mid-$70 million range, but there was speculation that the drug could hit $85 million to $90 million in sales in the third quarter. The drug had $68 million in U.S. sales in the second quarter. Idec said sales would be higher in the fourth quarter than in the third quarter, according to the hedge fund analyst, who was buying more Idec stock midday. Rastetter, who spoke at the breakout session, was not immediately available for comment. Idec was recently trading down 20 3/16, or 15%, at 116 1/2, while Genentech was off 7 1/2, or 4.3%, at 167 1/2.